Behcet’s patient-derived HLA class I immunopeptidome is ERAP1-dependent and displays disease-specific candidate peptides 4513

Le résumé fourni par la source

Abstract Description Specific HLA I (HLA-B51) confers risk for Behcet’s disease (BD), augmented by allotypic ERAP1 with low peptide trimming activity. We previously demonstrated the impact of ERAP1 KO on the HLA I/ B51 peptidome in a genome-edited in vitro model. Here, we aimed to extend our findings to native biospecimens and identify disease-associated peptides directly from humans. We immunoprecipitated HLA I-peptide from biomaterial of 103 Turkish donors (n BD = 86, n HD = 17), followed by mass spectrometry of HLA I-eluted peptides and determined ERAP1 allotypes. Group analyses included BD vs. HD and low vs. high trimmers, dependent on, or independent of, HLA-B51 carrier status. We compared peptide lengths and applied penalized logistic regression to identify BD-specific candidate peptides. Low ERAP1 activity was associated with longer peptides. Analysis of an independent cohort of BD/ HD HLA-B51 carriers revealed increased peptide lengths above 9mer in BD. A set of distinct HLA I-eluted peptides was found in approximately 40% of BD patients but not in HD. Penalized logistic regression identified peptides that differentiated BD from HD with high accuracy. We show that the HLA I peptidome is modulated by ERAP1 in actual human subjects rather than cell lines alone, with a propensity for longer peptides for low-trimming ERAP1 and HLA-B51+ BD. This peptidome includes potentially BD-specific, HLA I-restricted peptides, identifying targets for biomarker development and pathogenic T-cell recognition. Funding Sources R01EY031383 (Nowatzky), R01EY033495 (Nowatzky) Topic Categories Immune Mechanisms of Human Disease (HUM)

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.